Distinctive characteristics of XXXX ( @entity1149 ) in the young: a surveillance, epidemiology, and end results (SEER) analysis.

@entity1 @entity957 @entity1149 @entity420
BACKGROUND: The median age of @entity1 with newly diagnosed @entity1149 ( @entity1149 ) at presentation is 71 years. We conducted an analysis of Surveillance, Epidemiology, and End Results data to assess whether the presentation and outcomes of @entity1149 in younger @entity1 (age < or =40 years) are different from that in older @entity1 (age >40 years). METHODS: We obtained the demographic, clinical, and outcomes data for all @entity1 diagnosed with @entity1149 from 1988 to 2003 in the Surveillance, Epidemiology, and End Results registry. @entity1 were grouped by age at diagnosis into younger than or equal to 40 years (younger cohort) or older than 40 years (older cohort). RESULTS: During the period analyzed, we identified 2775 @entity1 with @entity1149 in the younger cohort and 236,313 @entity1 in the older cohort. Compared with the older group, the younger group had greater proportion of African Americans (19.2% versus 10.9%; p < 0.0001), Asian or Pacific Islander (10.3% versus 5.9%; p < 0.0001), @entity1 (48.7% versus 41.9%; p < 0.0001), and @entity1 with stage IV disease (57.4% versus 43.0%; p < 0.0001). @entity420 was more common in younger @entity1 than in the older @entity1 (57.5% versus 45.2%; p < 0.0001). @entity957 was less prevalent in the younger cohort than in older cohort (12.5% versus 26.4%; p < 0.0001). Five-year overall survival and cancer specific survival were significantly better for younger @entity1 than for older @entity1 across all stages. CONCLUSIONS: There is a greater representation of African Americans, Asians or Pacific Islanders, @entity1 , and @entity420 histology in the younger cohort of @entity1 with @entity1149 compared with the older cohort. Despite presenting with stage IV disease more often, the overall and cancer-specific survivals are better in younger cohort than in the older cohort.
